Literature DB >> 20422344

RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells.

Qin Xu1, Xiuming Liu, Yili Cai, Youcheng Yu, Wantao Chen.   

Abstract

A disintegrin and metalloproteinase 9 (ADAM9) is a type I transmembrane protein that has been associated with cancer development and metastases. Here, we show that ADAM9 is highly expressed in metastatic cancer tissues and in an adenoid cystic carcinoma cell line with a high metastatic potential. Using RNA interference for gene silencing, we show that ADAM9 is essential for in vitro cancer cell proliferation and invasion as well as in vivo cancer metastasis in an experimental murine model of lung metastases. These data indicate that ADAM9 is potentially an important new therapeutic target for the prevention of tumor metastases in adenoid cystic carcinoma.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20422344     DOI： 10.1007/s13277-010-0034-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  25 in total

Review 1.  Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature.

Authors:  Alexander D Rapidis; Nikolaos Givalos; Hariklia Gakiopoulou; Gregory Faratzis; Spyros D Stavrianos; George A Vilos; Emmanuel E Douzinas; Efstratios Patsouris
Journal:  Oral Oncol       Date:  2005-03       Impact factor: 5.337

2.  The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis.

Authors:  N Rocks; C Estrella; G Paulissen; F Quesada-Calvo; C Gilles; M M Guéders; C Crahay; J-M Foidart; P Gosset; A Noel; D D Cataldo
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

3.  Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.

Authors:  Kyle C Cuneo; Allie Fu; Katherine L Osusky; Ling Geng
Journal:  Anticancer Drugs       Date:  2007-03       Impact factor: 2.248

4.  Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.

Authors:  Uwe Lendeckel; Jana Kohl; Marco Arndt; Stacy Carl-McGrath; Hans Donat; Christoph Röcken
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-30       Impact factor: 4.553

5.  The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer.

Authors:  Stacy Carl-McGrath; Uwe Lendeckel; Matthias Ebert; Albert Roessner; Christoph Röcken
Journal:  Int J Oncol       Date:  2005-01       Impact factor: 5.650

6.  Critical function for ADAM9 in mouse prostate cancer.

Authors:  Lucie Peduto; Victor E Reuter; David R Shaffer; Howard I Scher; Carl P Blobel
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells.

Authors:  Junxia Chen; Huimin Peng; Xi Ou-Yang; Xiaoyan He
Journal:  Melanoma Res       Date:  2008-10       Impact factor: 3.599

8.  Identification of genes with consistent expression alteration pattern in ACC-2 and ACC-M cells by cDNA array.

Authors:  Dan Huang; Wantao Chen; Zhiyuan Zhang; Ping Zhang; Ronggen He; Xiaojian Zhou; Weiliu Qiu
Journal:  Chin Med J (Engl)       Date:  2003-03       Impact factor: 2.628

9.  Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma.

Authors:  Qin Xu; Zhiyuan Zhang; Ping Zhang; Wantao Chen
Journal:  BMC Cancer       Date:  2008-06-03       Impact factor: 4.430

10.  ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.

Authors:  Florian R Fritzsche; Kirsten Wassermann; Monika Jung; Angelika Tölle; Ilka Kristiansen; Michael Lein; Manfred Johannsen; Manfred Dietel; Klaus Jung; Glen Kristiansen
Journal:  BMC Cancer       Date:  2008-06-26       Impact factor: 4.430
View more
  10 in total

1.  Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer.

Authors:  Liang Chang; Fangchao Gong; Hongfei Cai; Zhihong Li; Youbin Cui
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

2.  Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.

Authors:  N Giebeler; A Schönefuß; J Landsberg; T Tüting; C Mauch; P Zigrino
Journal:  Oncogene       Date:  2017-05-29       Impact factor: 9.867

3.  Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Authors:  Elmina Mammadova-Bach; Paola Zigrino; Camille Brucker; Catherine Bourdon; Monique Freund; Adèle De Arcangelis; Scott I Abrams; Gertaud Orend; Christian Gachet; Pierre Henri Mangin
Journal:  JCI Insight       Date:  2016-09-08

4.  Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.

Authors:  T Kauttu; H Mustonen; S Vainionpää; L Krogerus; I Ilonen; J Räsänen; J Salo; P Puolakkainen
Journal:  Clin Transl Oncol       Date:  2016-03-30       Impact factor: 3.405

Review 5.  Snake venom disintegrins and cell migration.

Authors:  Heloisa S Selistre-de-Araujo; Carmen L S Pontes; Cyntia F Montenegro; Ana Carolina B M Martin
Journal:  Toxins (Basel)       Date:  2010-10-29       Impact factor: 4.546

6.  Preferred SH3 domain partners of ADAM metalloproteases include shared and ADAM-specific SH3 interactions.

Authors:  Iivari Kleino; Annika Järviluoma; Jussi Hepojoki; Ari Pekka Huovila; Kalle Saksela
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

7.  Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-126-3p Inhibits Pancreatic Cancer Development by Targeting ADAM9.

Authors:  Dong-Mei Wu; Xin Wen; Xin-Rui Han; Shan Wang; Yong-Jian Wang; Min Shen; Shao-Hua Fan; Zi-Feng Zhang; Qun Shan; Meng-Qiu Li; Bin Hu; Jun Lu; Gui-Quan Chen; Yuan-Lin Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2019-03-01       Impact factor: 10.183

Review 8.  Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.

Authors:  Mehrdad Nasrollahzadeh Sabet; Masood Movahedi Asl; Mahtab Kazemi Esfeh; Navid Nasrabadi; Maryam Shakarami; Behrang Alani; Asma Alimolaie; Sara Azhdari; Ebrahim Cheraghi
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

9.  A disintegrin and metalloproteinase 9 is involved in ectodomain shedding of receptor-binding cancer antigen expressed on SiSo cells.

Authors:  Kenzo Sonoda; Kiyoko Kato
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

10.  Disruption and inactivation of the PP2A complex promotes the proliferation and angiogenesis of hemangioma endothelial cells through activating AKT and ERK.

Authors:  Furong Xie; Xin Bao; Jingshuang Yu; Wantao Chen; Lizhen Wang; Zhiyuan Zhang; Qin Xu
Journal:  Oncotarget       Date:  2015-09-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.